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Background: Histidine-rich Glycoprotein (HRG) has previously been shown to have an impact on implantation
and fertility. The aim of this study was to investigate if there is an association between the HRG A1042G single
nucleotide polymorphism (SNP) and recurrent miscarriage.
Methods: The study was designed as a case-control study and the women were included at University Hospitals
in Sweden. 186 cases with recurrent miscarriage were compared with 380 pregnant controls with no history of
miscarriage. Each woman was genotyped for the HRG A1042G SNP.
Results: The results indicated that the frequency of heterozygous HRG A1042G carriers was higher among controls
compared to cases (34.7% vs 26.3%; p < 0.05). In a bivariate regression analysis, a negative association was found
between recurrent miscarriage and heterozygous A/G carriers both in the entire study population (OR 0.67, 95% CI
0.45 - 0.99; p < 0.05) as well as in a subgroup of women with primary recurrent miscarriage (OR 0.37, 95% CI 0.16 - 0.84;
p < 0.05). These results remained even after adjustment for known confounders such as age, BMI and thyroid disease
(OR 0.36, 95% CI 0.15 - 0.84; p < 0.05).
Conclusions: Women who are heterozygous carriers of the HRG A1042G SNP suffer from recurrent miscarriage more
seldom than homozygous carriers. Thus, analysis of the HRG A1042G SNP might be of importance for individual
counseling regarding miscarriage.
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Recurrent miscarriage was defined as three or more con-
secutive pregnancy losses before 20 weeks of gestation
[1]. Since then several guidelines have been launched
but their definitions vary regarding the number as well
as the sequence of preceding miscarriages; recurrent
miscarriage is defined as two or more versus three or
more consecutive pregnancy losses according to ACOG
[2] and ESHRE [3] as well as RCOG [4] respectively.
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It affects approximately 1-5% of fertile couples [1,7]
and the risk of recurrence increases with maternal age
and number of consecutive pregnancy losses [8]. The
reason for recurrent miscarriage on an individual basis
is often unclear, but parental and fetal chromosomal
aberrations, uterine abnormalities and immunological,
endocrinological and thrombophilic disorders play import-
ant role [3]. Although the condition is common, underlying
causes can only be determined in about 50% of the cases
[9]. Consequently, remaining cases are classified as idio-
pathic with a presumably heterogeneous and multifactorial
etiology [1]. Current research in this patient group hastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion as well as embryogenesis.
Angiogenesis, which refers to the formation of new
blood vessels from preexisting ones, is required during
embryonic development as well as in implantation and
placentation. Based on this hypothesis several studies
have been performed examining the potential contribution
of genetic polymorphisms encoding angiogenic media-
tors (such as VEGF, eNOS, p53 etc) [10,11]. One of the
endogenous regulators of angiogenesis circulating in
high levels in plasma is Histidine-rich Glycoprotein (HRG).
The protein is synthesized in the liver and it is either
transported as a free protein or stored in α-granules of
platelets and released after thrombin stimulation [12].
The human HRG gene is localized at chromosome 3 in
position 3q28-29 and it encodes a 507 amino acid long
multi-domain protein [13]. Structurally, HRG consists
of three distinct domains: a NH2-terminal part with
two cystatin-like domains, a central histidine/proline-
rich domain and a COOH-terminal domain [13]. It
interacts with a number of different biological pathways
such as regulation of chemotaxis and focal adhesion of
endothelial cells, cytoskeletal organization during vessel
formation and immune complex formation. Its action
is mediated by a variety of ligands including heparin/
heparan sulfate, thrombospondin, plasminogen and diva-
lent metal ions [13].
HRG might be involved in several of the processes of
importance for a pregnancy to occur but the exact role
of HRG in fertility is not yet fully described. We have
previously shown that HRG exists in the reproductive
system as well as in the embryo [14] and it is involved
in the hypercoagulability and the angiogenic imbalance
seen in early onset preeclampsia [15]. HRG has been
reported to exist as at least ten naturally occurring
single nucleotide polymorphisms (SNPs) [16,17]. One
of the SNPs, the HRG C633T SNP, has been postulated
to be of relevance for implantation and a successful
pregnancy [18] and there is an increased occurrence of
the homozygous T/T genotype in patients with primary
recurrent miscarriage [19].
In another SNP of the gene, named HRG A1042G, an
adenine (A) nucleotide is replaced by a guanine (G), which
results in a change from histidine to arginine at amino
acid position 340 in the protein. HRG A1042G is localized
in the histidine/proline (His/Pro) rich region, which is
known to mainly regulate the anti-angiogenic capacity of
HRG [20]. No study has, however, been performed yet
examining its importance in pregnancy. Since adequate
regulation of angiogenesis is well known to be of relevance
for implantation and placentation, as well as for embryo-
genesis, the aim of this study was to investigate if there
is an association between the HRG A1042G SNP and
recurrent miscarriage.Methods
Study population
The study was designed as a case-control study. Cases
(n = 186) were recruited from the Department of Obstetrics
and Gynaecology at Uppsala University Hospital, Karolinska
University Hospital, Huddinge University Hospital and
Danderyd University Hospital, Sweden. Eligible cases with
a diagnosis of recurrent miscarriage, defined as three or
more verified consecutive miscarriages in the first or
second trimester of pregnancy (5-21 completed weeks
of gestation), were identified in the out-patient registers
of the participating clinics and invited to participate in
the study. The women were included between April 29,
2009 and June 30, 2010 sometimes years after the initial
incidence. Women with known risk factors for recurrent
miscarriage, such as systemic lupus erythematosus, diabetes
mellitus type 1, severe thrombophilia and major chromo-
somal aberrations were not included in the study.
The control subjects (n = 380) were randomly chosen
from the Uppsala University Hospital biobank of pregnant
women. Since May 31, 2007, all women aged 18 and older
attending the second trimester (16-19 weeks of gestation)
routine ultrasound scan at Uppsala University Hospital
have been approached for inclusion in this biobank, and
inclusion to our study was ongoing until June 30, 2010.
All control subjects were followed until delivery and only
term pregnancies fulfilled the inclusion criteria. In the
control group, no woman had a history of miscarriage or
was treated with anti-thrombophilic medication (such
as Low Molecular Weight Heparin or Aspirin) and 75%
had at least two spontaneous pregnancies, including the
ongoing pregnancy, resulting in a term (≥37 weeks) birth
of a live infant. Thirty-two percent of our cases had
already a child before recruitment. Cases and controls
differed only in their obstetric record but had otherwise
similar inclusion and exclusion criteria.
Both cases and controls attended a brief health examin-
ation including measurements of weight and height and
answered standardized questions on reproductive history.
Furthermore, we reviewed the medical records to obtain
relevant information on pregnancy outcomes, health
problems and medication. According to routine clinical
procedures, TSH-levels were analysed in all women
when diagnosed with recurrent miscarriage. Among
cases hypothyroidism was defined as TSH above the
current defined upper limit of the reference range at
the different hospitals. Pregnant controls at high risk
for thyroid disease were subjected to selected TSH
screening according to local guidelines based on inter-
national recommendations. This case-finding procedure
was applied in first or early second trimester of pregnancy,
before routine ultrasound scan and inclusion in the study.
Since ethnicity affects genetic variation, the population
distribution was then investigated on our study group.
Table 1 Background characteristics of the study population
Cases (n = 186) Controls (n = 380)
Age, years 30.1 ± 5.7 30.1 ± 5.7
BMI, kg/m2* 24.7 ± 4.8 23.8 ± 4.0
Smokers, n (%)* 34 (18.3%) 41 (10.8%)
Hypothyroidism, n (%)** 16 (8.6%) 12 (3.2%)
HRG A1042 genotype
A/A 128 (68.8%) 231 (60.8%)
A/G* 49 (26.3%) 132 (34.7%)
G/G 9 (4.8%) 17 (4.5%)
Values are mean ± standard deviation; n, number of women; BMI, body mass index
(missing data in 1 subject) at the recruiting time for cases or at the first antenatal
visit for the controls; Pre-pregnancy smokers, smoker during≥ 1 pregnancy ending
with miscarriage for the cases or at first visit to the prenatal center in gestational
week 10 for the controls.
*p < 0.05, **p < 0.01.
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(363/380) of controls were of Caucasian origin and the
frequency did not differ statistically between the two
groups (p = 0.89). All the analyses that follow are performed
in an ethnically mixed group.
A post hoc power calculation, where a Chi-square test
with an alpha-value of 0.05 was used, gave a post hoc
power of 0.97.
The study was approved by the Regional Ethical Review
Boards in Uppsala and Stockholm, Sweden. Informed con-
sent was obtained from all women included in the study.
No reimbursement was given to participating patients.
Blood sample collection
Blood samples were collected in EDTA-containing tubes
and centrifuged at 1500 g for 10 min. Plasma and buffy
coat were separated, transferred to new tubes and stored
at -20°C.
SNP analysis
Genomic DNA was extracted from buffy coat using QIamp
DNA Blood Maxi kits (Qiagen, venlo, the Netherland).
The samples were genotyped for the HRG A1042G
(rs2228243), using the TaqMan SNP Genotypning Assay
(Applied Biosystems, Foster city, CA, USA). Briefly, poly-
merase chain reactions were performed in a 96-well plate
in total volume of 25 μl for each well. Each reaction
consisted of 1xTaqMan Universal PCR Master Mix (PCR
buffer, ROX passive reference dye, dNTPs and AmpliTaq
Gold polymerase), 1× SNP Genotyping Assay (sequence-
specific forward and reverse primers to amplify the
polymorphic sequence of interest, ie HRG exon 5, Taq
man MGB probes labelled with VIC dye to detect allele
1 sequence and with FAM to detect allele 2 sequence)
and 10 ng of genomic DNA. Cycling conditions were
initiated for 10 min at 95°C followed by 40 cycles of
15 s at 92°C and 1 min at 60°C. Real-time fluorescence
detection was performed. Sequence Detection system
Software (Applied Biosystems) was used to plot fluores-
cence (Rn) values based on the signals from each well.
The plotted fluorescence signals indicated which alleles
were present in each sample.
Statistical analysis
Demographic and clinical characteristics were compared
between cases and controls or genotype groups using
Student’s t-test, Mann-Whitney U test, Chi square test
and Kruskal-Wallis test. At first, a logistic regression ana-
lysis was performed examining the association between
HRG A1042G SNPs and recurrent miscarriage. Secondly,
in a subgroup analysis where only women with primary
recurrent miscarriage were included (defined as recurrent
miscarriage and no known children either before or after
diagnosis), a comparison with controls was performedusing Student’s t-test and Chi-square test. A logistic
regression model was composed. A number of possible
confounders were considered for inclusion in the regres-
sion model; age, pre-pregnancy smoking, BMI, thyroid
disease and genotype. Only variables with a possible
association with exposure and outcome (p-value < 0.25)
were entered into the final model. Adjusted odds ratios
(AOR) for recurrent miscarriage were calculated in logistic
regression analyses including the following variables:
maternal age as completed years at the first pregnancy or
first miscarriage (two categories, ≤ 35 years or > 36 years),
body mass index (BMI, kg/m2) defined as BMI recorded
at inclusion (cases) or BMI at first antenatal visit (controls)
(two categories, ≤ 30 kg/m2 or > 31 kg/m2), smoking
during pregnancy (yes/no) defined as smoker during ≥ 1
pregnancy ending with miscarriage (cases) or smoker at
first visit to the prenatal center in gestational week 10
(controls), and genotype (two categories, heterozygous
compared to homozygous HRG A1042 SNP and HRG
1042G SNP). A p-value < 0.05 was considered as significant.
All statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) 20.0 for Windows
software pack (SPSS, Chicago, IL).Results
Background characteristics and HRG genotype
Demographic data and clinical characteristics concerning
cases (n = 186) and controls (n = 380) are shown in Table 1.
There was no difference in age between cases and con-
trols. BMI was higher among cases (24.7 vs 23.8; p < 0.05),
and as expected, hypothyroidism was more common in
women with recurrent miscarriage (8.6% vs 3.2%; p < 0.01).
All women were genotyped according to the HRG A1042G
SNP and the frequency of heterozygous (A/G) carriers
was significantly higher among controls compared to cases
(34.7% vs 26.3%; p < 0.05, Table 1).
Table 3 Factors associated with recurrent miscarriage in
association with HRG A1042G genotype in a subgroup





≤35 years 1 1
≥36 years 1.31 (0.63-2.71) 1.40 (0.65-2.96)
BMI, kg/m2
≤30 1 1
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SNP, 359 (63.4%) of them were homozygous for adenine
(A/A), 181 (32%) were heterozygous (A/G) and 26 (4.6%)
were homozygous for guanine (G/G) (Table 2). The num-
ber of homozygous and heterozygous carriers of the SNP
was in accord with the Hardy-Weinberg equilibrium.
BMI, age and smoking did not differ in relation to geno-
type. Hypothyroidism was more prevalent among the
homozygous G/G carriers (Table 2).
Genotype and risk for recurrent miscarriage
At first, a logistic regression analysis in the entire study
population was performed where an association between
genotype and the condition of recurrent miscarriage was
identified. The heterozygous A/G carriers presented the
lowest risk compared to A/A or G/G carriers (OR 0.67,
95% CI 0.46 - 0.99; p < 0.05).
In order to study recurrent miscarriage as a reason for
sub-fertility, a statistical subgroup was constructed. This
group was defined as ‘diagnosed with primary recurrent
miscarriage’ (no known children either before or after
diagnosis) [19,21], and consisted of 43 women who were
compared to controls. Age, BMI and smoking did not
differ between the groups, but hypothyroidism was more
prevalent (p < 0.001) among cases. The frequency of het-
erozygous A/G carriers was significantly lower among
controls than cases (34.7% vs 16.3%, p < 0.05). To further
investigate the impact of the HRG A1042G SNP on
recurrent miscarriage a logistic regression analysis was
performed on this subgroup of women. A significant
association between women carrying the heterozygous
HRG A1042G SNP and recurrent miscarriage was iden-
tified, with a decreased risk of recurrent miscarriage
among these women (OR 0.37, CI 95% 0.16-0.84; p < 0.05).
As expected, hypothyroidism was associated positively
with recurrent miscarriage (OR 4.97 CI 95% 1.76-14.02;
p < 0.01). Other known confounders such as age, smoking
and BMI were not associated with recurrent miscarriageTable 2 Demographic data and clinical characteristics of








Age, years 30.0 ± 5.8 30.2 ± 5.8 30.7 ± 5.0
BMI at first antenatal visit, kg/m2 24.4 ± 4.4 23.6 ± 4.0 23.9 ± 4.8
Pre-pregnancy smokers, n (%) 45 (12.5%) 27 (14.9%) 3 (11.5%)
Hypothyroidism, n (%)* 16 (4.5%) 8 (4.4%) 4 (15.4%)
Recurrent miscarriage* 128 (35.7%) 49 (27.1%) 9 (34.6%)
Recurrent miscarriage without child* 32 (12.2%) 7 (5%) 4 (19%)
Values are mean ± standard deviation; n, number of women; BMI, body mass
index; Pre-pregnancy smokers for cases or smoker at first visit to the prenatal
center in gestational week 10 for the controls.
*p < 0.05.(Table 3). The women with the heterozygous HRG A1042G
SNP were furthermore shown, after performing a logistic
regression analysis adjusted for the above mentioned
known confounders, to be protected from recurrent
miscarriage (OR 0.36, 95% CI 0.15-0.84; p < 0.05).
Discussion
In the present study, a possible association between the
HRG A1042G SNP and recurrent miscarriage has been
investigated. We found that among women with recurrent
miscarriage there was a decreased occurrence of heterozy-
gous HRG A1042G SNP carriers and the association
was even stronger in the group with primary recurrent
miscarriage. Previous computational studies have shown
that the amino acid shift in position 340 related to that
specific SNP is predicted to be benign or tolerated accord-
ing to Polyphen-2 and SIFT respectively (position-specific
independent count score 0.227 and tolerance index 0.34)
[22]. The latter is partly in agreement with our finding
that heterozygous A/G carriers have a lower occurrence
of recurrent miscarriage compared to homozygous A/A.
Further in vitro studies are required to investigate the
underlying mechanisms and the mediators involved in the
increased risk of recurrent miscarriage in homozygous
G/G compared to heterozygous A/G carriers. It should
nevertheless be reminded that recurrent miscarriage is≥31 1.86 (0.77-4.48) 1.99 (0.80-4.95)
Smoking
No 1 1
Yes 2.19 (0.98-4.89) 2.37 (1.04–5.44)*
Hypothyroidism
No 1 1
Yes 4.97 (1.76-14.02)** 4.63 (1.61–13.36)**
HRG A1042G genotype
A/A or G/G 1 1
A/G 0.37 (0.16-0.84)* 0.36 (0.15-0.84)*
BMI, body mass index; Pre-pregnancy smokers for cases, or smoker at first visit to
the prenatal center in gestational week 10 for controls; HRG A1042G genotype
refers to either heterozygous carriers (A/G) or homozygous carriers (A/A) or (G/G).
Adjusted for age, BMI, smoking and thyroid disease.
*p < 0.05, **p < 0.01.
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not a Mendelian disease. Therefore it might be related
to various genetic polymorphisms and their combinations
and not solely on a single one. Our results are in agreement
with the theory of heterozygote advantage according to
which heterozygous carriers present a selective advantage
in viability and reproductive fitness over homozygous in
natural populations [23]. Although the hypothesis of “het-
erozygosity-fitness” correlation has mainly been associated
with disease resistance in evolutionary biology, some recent
reports describe possible associations between specific
polymorphisms and fertility [24,25]. A similar reproductive
advantage among HRG heterozygous carriers cannot be
ruled out.
The establishment of a pregnancy requires adequate
regulation of angiogenesis, coagulation, as well as regula-
tion of immunological pathways [3]. Development of a
normal well functioning vasculature in the uterus and
placenta requires cooperation between different cell types
and various growth factors in the processes of implant-
ation, embryo development and placentation. The exact
coordination of these processes is complex, which is
further indicated by the fact that a defect in one single
factor that may interact with others might induce preg-
nancy failure [26]. In microarray analyses on endometrial
biopsies [27] as well as decidual samples [28] from women
with recurrent miscarriage, it has been shown that genes
from different functional areas have been inadequately
regulated, with the most important genes being related
to control of cell adhesion, cell migration and angio-
genesis. In addition, studies evaluating the role of gene
polymorphisms coding for the most known mediators
of angiogenesis such as VEGF, eNOS and p53 tend to
find positive associations to the condition [10,11].
We have previously shown that HRG might be of im-
portance in early pregnancy and this is supported by our
prior results indicating an association between the pres-
ence of HRG in placenta and risk of preeclampsia during
pregnancy [15], as well as between the HRG C633T SNP
and pregnancy outcome among patients undergoing
in vitro fertilization [18].
The HRG A1042G SNP studied in this manuscript,
which corresponds to a mutation in the His/Pro rich
domain of HRG, was of interest based on previous know-
ledge indicating that this domain of HRG is important
for the regulation of angiogenesis. Van Wildemeersch
et al. [29] has presented evidence that a 35 amino acid
long synthetic peptide corresponding to amino acids
330-364 in HRG located to the His/Pro rich domain,
exhibited a Zn2+- dependent inhibitory effect on vessel
formation both in vitro and in vivo. HRG 330-364 attached
to heparin/heparan sulfate with equal capacity as full-
length HRG. Peptides corresponding to other regions
than the His/Pro-rich region of HRG-downstream ofHRG 330-364 -lacked this inhibitory effect on endothelial
cell migration and displayed a notably reduced heparin-
binding capacity. The importance of this region in HRG
was furthermore confirmed by Lee et al. [30]. They
described that this region of HRG corresponds to the
minimal anti-angiogenic active HRG fragment that is
required for activation of endothelial cell focal adhesion,
whereas changes in the region disrupt the cytoskeletal
organization and the capacity of endothelial cells to
assemble into vessel structures [31]. The latter is also
in agreement with the concept that angiogenesis re-
quires migration of endothelial cells [32] which is sig-
nificant for implantation/placentation. In inadequately
regulated placentation, pregnancy complications often
develop. In summary, these studies suggest a connection
between HRG and control of angiogenesis through release
of the His/Pro rich region via a proteolytically regulated
mechanism.
The exact pathway by which HRG exhibits its anti-
angiogenic effect is not yet fully described; it seems
nevertheless to be carried out through simultaneous
multifactorial interaction. The His/Pro-rich region of HRG
has been proposed to act through binding of cells at
sites of tissue injury and thereby regulating the activity
of degradative enzymes such as the plasminogen/plasmin
system [33]. However, recent studies indicate that proteoly-
sis mediated solely by plasmin is not sufficient to release
the anti-angiogenic fragment of HRG due to the presence
of an interdomain disulfide bridge connecting the NH2
domain to the His/Pro rich region [34]. Kassaar et al
[34] with the use of x-ray crystallography has revealed the
presence of an S-glutathionyl adduct at a cysteine residue
(Cys185) of HRG, promoting the plasmin-mediated
cleavage of the His/Pro fragment through a reduction/
oxidation mechanism [34]. Although HRG has not been
widely studied in the context of pregnancy or placental
function, but mostly in tumors and carcinogenesis, similar
conditions are thought to prevail in both situations. In
conditions with limited supply of oxygen and nutrients
(such as in tumors) treatment with recombinant human
HRG led to reduced vascularization, increased apoptosis
and decreased proliferation [32]. This was also confirmed
by Juarez et al [20] who described that the anti-angiogenic
effect of HRG, localized specifically to the His/Pro rich
region, is mediated via increased activity of caspase-3-a
and as a consequence via induced apoptosis of endothelial
cells [20].
Another factor that stimulates the anti-angiogenic
effect of HRG has been described to be blood platelets
in an activated state. Activated maternal platelets were
found in the lumen of the spiral arteries after histological
examination of human placental tissue [35]. In an activated
state, platelets release a variety of growth factors, cytokines
and ions stored in granules. A local increase in Zn2+
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His/Pro rich domain and hence promote its binding to
endothelial cells via heparan sulfate [12,20].
Despite the latter, one should always be cautious in
interpreting genetic associations since there is always a
possibility that the reported results represent a chance
finding. It should however be noted that the background
to the current hypothesis is based on a robust and widely
accepted association between recurrent miscarriage and
impaired implantation/placentation, due to inadequate
angiogenesis [26]. One of the limitations with this study
might be that a fraction of data is based on clinical
information which is self-reported by the patients, in
many cases years after the initial diagnosis, and we are
thus obliged to accept that there might be a recall bias.
On the other hand, this case-control study contains a
very well defined and ethnically homogeneous population
that strengthens the associations noted. Furthermore the
ethnical distribution of the genetic variation in our study
group is consistent with the distribution in HapMap-CEU
population (rs2228243) [36], a population with similar
geographic origin. Additional studies are though needed
to further confirm our results as well as investigate the
exact pathophysiological mechanism by which HRG
variants are associated to recurrent miscarriage.
In conclusion, our results indicate an important role
for HRG A1042G SNP in early pregnancy. It is shown
that women who are heterozygous carriers of the HRG
A1042G SNP suffer from recurrent miscarriage more
seldom than homozygous carriers. Thus, analysis of the
HRG A1042G SNP might be of importance for individual
counseling regarding miscarriage.
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